Abstract
Human Genome Sciences and GlaxoSmithKline, under license from Cambridge Antibody Technology, are developing mapatumumab, the intravenously administered lead from a series of human monoclonal antibody tumor necrosis factor-related apoptosis-inducing ligand receptor 1 agonists, for the potential treatment of cancer. The therapy is currently undergoing phase II clinical trials. Takeda is developing mapatumumab in Japan.
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacokinetics
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / therapeutic use*
-
Apoptosis / drug effects
-
Apoptosis Regulatory Proteins / agonists
-
Apoptosis Regulatory Proteins / immunology*
-
Apoptosis Regulatory Proteins / pharmacology
-
Cell Line, Tumor
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Contraindications
-
Dose-Response Relationship, Drug
-
Humans
-
Membrane Glycoproteins / agonists
-
Membrane Glycoproteins / immunology*
-
Membrane Glycoproteins / pharmacology
-
Neoplasms / drug therapy*
-
TNF-Related Apoptosis-Inducing Ligand
-
Tumor Necrosis Factor-alpha / agonists
-
Tumor Necrosis Factor-alpha / immunology*
-
Tumor Necrosis Factor-alpha / pharmacology
-
Xenograft Model Antitumor Assays
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Apoptosis Regulatory Proteins
-
Membrane Glycoproteins
-
TNF-Related Apoptosis-Inducing Ligand
-
TNFSF10 protein, human
-
Tumor Necrosis Factor-alpha
-
mapatumumab